563 ICT01, an anti-BTN3A mAb, and NL-201, an alpha-independent IL-2/IL-15 agonist, combine to elicit a potent anti-tumor response by synergistically stimulating Vg9Vd2 T cell activation and proliferation

• Ryan Swanson,
• Aude de Gassart,
• Patrick Brune,
• Sophie Agaugué,
• Paul Frohna,
• Loui Madakamutil,
• Maelle Mairesse,
• Carl Walkey

Affiliations

Ryan Swanson

Aff688 Alpine Immune Sciences Seattle WA USA

Aude de Gassart

1ImCheck Therapeutics, Marseille, France

Patrick Brune

1Imcheck Therapeutics, Marseille, France

Sophie Agaugué

1Imcheck Therapeutics, Marseille, France

Paul Frohna

1Imcheck Therapeutics, Marseille, France

Loui Madakamutil

Research Biology: Pharmacology, Nektar Therapeutics, San Francisco, California, USA

Maelle Mairesse

1ImCheck Therapeutics, Marseille, France

Carl Walkey

2Neoleukin Therapeutics Inc, Seattle, WA, USA